Phase III study of tislelizumab plus chemotherapy vs chemotherapy alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC).

被引：4
|
作者：
Wang, Jie
Yu, Xinmin
Lu, Shun
Hu, Yanping
Sun, Yuping
Wang, Zhijie
Zhao, Jun
Yu, Yan
Hu, Chunhong
Yang, Kunyu
Feng, Guosheng
Ying, Kejing
Zhuang, Wu
Zhou, Jianying
Wu, Jingxun
Wu, Yanjie
Lin, Xiao
Liang, Liang
Yang, Nong
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hubei Canc Hosp, Wuhan, Peoples R China
[5] Jinan Cent Hosp, Jinan, Shandong, Peoples R China
[6] Minist Educ, Key Lab Carcinogenesis & Translat Res, Beijing, Peoples R China
[7] Peking Univ, Dept Thorac Med Oncol, Canc Hosp & Inst, Beijing, Peoples R China
[8] Harbin Med Univ, Canc Hosp, Harbin, Peoples R China
[9] Cent South Univ, Hosp 2, Changsha, Peoples R China
[10] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China
[11] Peoples Hosp Guangxi Zhuang Autonomous Reg, Nanning, Peoples R China
[12] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[13] Fujian Tumor Hosp, Fuzhou, Peoples R China
[14] Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[15] Xiamen Univ, Affiliated Hosp 1, Xiamen, Fujian, Peoples R China
[16] BeiGene Beijing Co Ltd, Beijing, Peoples R China
[17] Cent South Univ, Xiangya Sch Med, Affiliated Canc Hosp, Hunan Canc Hosp, Changsha, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9554
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Wu, X.
    Cui, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S817 - S817
  • [2] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small Cell Lung Cancer
    Wang, J.
    Lu, S.
    Hu, C.
    Sun, Y.
    Yang, K.
    Chen, M.
    Zhao, J.
    Yu, G.
    Zhou, X.
    Feng, G.
    Pan, Y.
    Yu, Y.
    Zhang, J.
    Liang, L.
    Lin, X.
    Cui, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S3 - S3
  • [3] RATIONALE 307: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for advanced squamous non-small cell lung cancer (sq NSCLC) in patients (pts) who were smokers vs non-smokers
    Yu, X.
    Wang, J.
    Lu, S.
    Zhao, J.
    Yu, Y.
    Hu, C.
    Feng, G.
    Ying, K.
    Zhuang, W.
    Zhou, J.
    Wu, J.
    Leaw, S. J.
    Lin, X.
    Zhang, J.
    ANNALS OF ONCOLOGY, 2021, 32 : S1005 - S1005
  • [4] Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non-Small-Cell Lung Cancer A Phase 3 Randomized Clinical Trial
    Wang, Jie
    Lu, Shun
    Yu, Xinmin
    Hu, Yanping
    Sun, Yuping
    Wang, Zhijie
    Zhao, Jun
    Yu, Yan
    Hu, Chunhong
    Yang, Kunyu
    Feng, Guosheng
    Ying, Kejing
    Zhuang, Wu
    Zhou, Jianying
    Wu, Jingxun
    Leaw, Shiang Jiin
    Zhang, Jing
    Lin, Xiao
    Liang, Liang
    Yang, Nong
    JAMA ONCOLOGY, 2021, 7 (05) : 709 - 717
  • [5] RATIONALE 304: Tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone as first-line (1L) treatment for non-squamous (non-sq) non-small cell lung cancer (NSCLC) in patients (pts) who are smokers vs non-smokers
    Lu, S.
    Huang, D.
    Chen, X.
    Wang, B.
    Xue, J.
    Wang, J.
    Bao, Y.
    Liang, L.
    Qiu, X.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2021, 32 : S1000 - S1001
  • [6] Tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
    Lu, S.
    Yu, Y.
    Yu, X.
    Hu, Y.
    Ma, Z.
    Li, X.
    Zhuang, W.
    Liu, Y.
    Li, W.
    Cui, J.
    Wang, D.
    Liao, W.
    Wang, M.
    Zhou, J.
    Wang, Z.
    Sun, Y.
    Gao, J.
    Bao, Y.
    Liang, L.
    Wang, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S816 - S817
  • [7] Trilaciclib Prior to Chemotherapy Plus Tislelizumab as 1L Treatment for Advanced Squamous Non-Small-Cell Lung Cancer
    Wang, Y.
    Shi, H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S640 - S640
  • [8] Tislelizumab plus chemotherapy is more cost-effective than chemotherapy alone as first-line therapy for advanced non-squamous non-small cell lung cancer
    Liang, Xueyan
    Chen, Xiaoyu
    Li, Huijuan
    Li, Yan
    FRONTIERS IN PUBLIC HEALTH, 2023, 11
  • [9] Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous non-small-cell lung cancer: final analysis of the randomized, phase III RATIONALE-307 trial
    Wang, J.
    Lu, S.
    Yu, X.
    Hu, Y.
    Zhao, J.
    Sun, M.
    Yu, Y.
    Hu, C.
    Yang, K.
    Song, Y.
    Lin, X.
    Liang, L.
    Leaw, S.
    Zheng, W.
    ESMO OPEN, 2024, 9 (10)
  • [10] RATIONALE 304: Tislelizumab (TIS) plus chemotherapy versus chemotherapy alone as first-line (1L) treatment for non-squamous (non-sq) NSCLC in patients (pts) aged 65-75 years
    Lu, Shun
    Wang, Jie
    Yu, Yan
    Yu, Xinmin
    Hu, Yanping
    Ma, Zhiyong
    Li, Xingya
    Zhuang, Wu
    Liu, Yunpeng
    Li, Weidong
    Cui, Jiuwei
    Wang, Dong
    Liao, Wangjun
    Wang, Mengzhao
    Zhou, Jianying
    Wang, Zhehai
    Sun, Yuping
    He, Wanyu
    Bao, Yuanyuan
    CANCER RESEARCH, 2022, 82 (12)
12345